Table 1.
Subject Characteristics
| Characteristic | Baseline | Sample Size at Baseline | 6 Months | Sample Size at 6 Months |
|---|---|---|---|---|
| Sex: | 372 | 216 | ||
| Male | 284 (76.3%) | 168 (77.8%) | ||
| Female | 88 (23.7%) | 48 (22.2%) | ||
| Age (years): | 59.8 (10.9)a | 372 | 58.8 (11.1)a | 216 |
| Race: | 372 | 216 | ||
| White | 309 (83.1%) | 173 (80.1%) | ||
| Black | 33 (8.9%) | 18 (8.3%) | ||
| Multiracial | 5 (1.3%) | 4 (1.9%) | ||
| Asian | 16 (4.3%) | 14 (6.5%) | ||
| Native Hawaiian | 1 (0.3%) | 1 (0.5%) | ||
| Native American | 1 (0.3%) | 1 (0.5%) | ||
| Don’t Know/Declined | 7 (1.9%) | 5 (2.3%) | ||
| Ethnicity: | 372 | 216 | ||
| Hispanic | 18 (4.8%) | 6 (2.8%) | ||
| Non-Hispanic | 354 (95.2%) | 210 (97.2%) | ||
| Type of Cancer: | 369 | 215 | ||
| SCC | 302 (81.8%) | 180 (83.7%) | ||
| SGC | 43 (11.7%) | 23 (10.7%) | ||
| Non-SCC/Non-Salivary | 24 (6.50%) | 12 (5.58%) | ||
| Primary Site of RT: | 360 | 213 | ||
| Base of Tongue | 71 (19.7%) | 40 (18.6%) | ||
| Buccal/Labial Mucosa | 7 (1.9%) | 3 (1.4%) | ||
| Epiglottis | 1 (0.3%) | 0 (0%) | ||
| Floor of Mouth | 3 (0.8%) | 0 (0%) | ||
| Gingiva/Alveolar Ridge | 1 (0.3%) | 1 (0.5%) | ||
| Hard Plate | 4 (1.1%) | 3 (1.4%) | ||
| Hypopharynx | 9 (2.5%) | 5 (2.3%) | ||
| Larynx | 18 (5.0%) | 11 (5.1%) | ||
| Lip | 3 (0.8%) | 1 (0.5%) | ||
| Mandible | 2 (0.6%) | 2 (0.9%) | ||
| Maxilla | 2 (0.6%) | 2 (0.9%) | ||
| Maxillary Sinus | 2 (0.6%) | 1 (0.5%) | ||
| Nasal Cavity | 1 (0.3%) | 0 (0%) | ||
| Nasopharynx | 23 (6.4%) | 17 (7.9%) | ||
| Neck | 44 (12.2%) | 27 (12.6%) | ||
| Oral Cavity | 7 (1.9%) | 3 (1.4%) | ||
| Oral Tongue | 20 (5.6%) | 9 (4.2%) | ||
| Oropharynx | 25 (6.9%) | 17 (7.9%) | ||
| Paranasal Sinus/Orbit | 0 (0%) | 0 (0%) | ||
| Parotid | 30 (8.3%) | 17 (7.9%) | ||
| Pharynx | 4 (1.1%) | 3 (1.4%) | ||
| Retromolar Trigone | 1 (0.3%) | 1 (0.5%) | ||
| Soft Palate | 0 (0%) | 0 (0%) | ||
| Sublingual Gland | 0 (0%) | 0 (0%) | ||
| Submandibular Gland | 5 (1.4%) | 3 (1.4%) | ||
| Tonsil | 63 (17.5%) | 41 (19.1%) | ||
| Other | 14 (3.9%) | 6 (2.8%) | ||
| Type of RT | 360 | 213 | ||
| IMRT w/ image guidance | 299 (83.1%) | 168 (78.9%) | ||
| IMRT w/o image guidance | 32 (8.9%) | 25 (11.7%) | ||
| 3-D Conformal radiation | 19 (5.3%) | 7 (3.3%) | ||
| Proton | 27 (7.5%) | 19 (8.9%) | ||
| Other | 1 (0.3%) | 1 (0.5%) | ||
| Total RT dose to primary site (cGy) | 6577 (703)a | 360 | 6639 (575)a | 213 |
| RT to primary site | 360 | 213 | ||
| Unilateral | 237 (65.8%) | 142 (66.7%) | ||
| Bilateral | 123 (34.2%) | 71 (33.3%) | ||
| Surgery prior to RT | 360 | 213 | ||
| No | 158 (43.9%) | 90 (42.3%) | ||
| Yes | 202 (56.1%) | 123 (57.7%) | ||
| Chemotherapy Received | 360 | 213 | ||
| No | 120 (33.3%) | 76 (35.7%) | ||
| Yes | 240 (66.7%) | 137 (64.3%) | ||
| Before start of RT | 92 (25.6%) | 53 (24.9%) | ||
| During RT | 237 (65.8%) | 136 (63.8%) | ||
| Both | 89 (24.7%) | 52 (24.4%) |
a
Table entries are average (SD).